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Myoblastular dystrophy (FSHD) is an autosomal dominant neuromuscular disease. It
maps to the D4Z4 repeat array at 4q35, and correlates with a repeat contraction which derepresses
transcription of local genes. Which, if any, of these genes is pathogenic to muscle, and through what
molecular mechanism is unknown. The present study investigates the function of one candidate gene,
DUX4c, encoded by a truncated inverted D4Z4 element located 42 kb proximal to the D4Z4 repeats. Using
a gain of function approach we tested DUX4c for toxicity and effects on differentiation in C2C12
myoblasts. DUX4c-expressing myoblasts appear morphologically normal but have reduced expression of
myogenic regulators, including MyoD and Myf5. Consistent with this, DUX4c-expressing myoblasts are
unable to differentiate into myotubes. Furthermore, overexpression of Myf5 or MyoD rescued myoblast
differentiation, suggesting that reductions in expression of these regulators are the relevant DUX4c-
induced physiological changes that inhibit differentiation. Our results suggest that upregulation of DUX4c
can have a deleterious effect on muscle homeostasis and regeneration, and point to a possible role for
DUX4c in the pathology of FSHD.
© 2008 Elsevier Inc. All rights reserved.IntroductionFacioscapulohumeral muscular dystrophy (FSHD) is a dominant
inherited neuromuscular disease with a prevalence of 1 in 20,000,
which makes it the third most common myopathy. It is characterized
by uneven and progressive weakness and atrophy of facial, shoulder
and upper arm muscle as well as in some cases with retinovasculo-
pathy, mental retardation and epilepsy. The underlying molecular
mechanism of the disease is still unknown but 95% of patients carry a
subtelomeric deletion on chromosome 4q35 (Wijmenga et al., 1992).
This region is mainly composed of a tandem repeat array consisting of
3.3 kb units (D4Z4). Each D4Z4 unit is GC rich and contains a repetitive
element related to the heterochromatic LSau sequence and binding
sites for a transcriptional repressor complex containing YY1, HMGB2,
and nucleolin (Gabellini et al., 2002). In the unaffected population, the
D4Z4 repeat array is polymorphic and may contain between 11 and
over 100 U. Due to internal deletions, FSHD patients carry only 1 to
10 U (Hewitt et al., 1994).
One of the prevailing models for the mechanism of FSHD is that
the normally large D4Z4 array nucleates a repressive chromatin
and contractions of this array disable this repression, resulting in
upregulation or derepression of local genes. Consistent with thisl rights reserved.model, Gabellini et al. observed that 2 nearby genes (FRG1 and FRG2)
and one gene from 5 Mb upstream (ANT1) were upregulated in FSHD
muscle (Gabellini et al., 2002). Furthermore, over expression of FRG1
from the human skeletal actin promoter was later shown to be
deleterious, leading to muscular dystrophy phenotype in transgenic
mice (Gabellini et al., 2006). However, the relevance of this transgenic
model, which has very high-level expression of FRG1 to FSHD
pathology, has been debated as similar levels of FRG1 have not been
demonstrated in FSHD muscle.
The D4Z4 repeats contain an open reading frame with two
homeoboxes (DUX4) (Gabriels et al., 1999). Homeodomain proteins
regulate many important developmental processes including muscle
development (Buckingham et al., 2003). Remarkably the home-
odomains of DUX4 have a high degree of similarity with Pax3 and
Pax7, the critical homeodomain regulators of muscle development
and regeneration. Recently, expression of DUX4 RNA and protein have
been selectively detected in primary myoblasts from FSHD patients
suggesting its involvement in FSHD (Kowaljow et al., 2007; Dixit et al.,
2007). Furthermore over expression of DUX4 in different cell lines
induced apoptosis (Kowaljow et al., 2007). A truncated and inverted
D4Z4 repeat is located approximately 42 kb centromeric from the
tandem D4Z4 repeats and just proximal of FRG2 (Fig. 1A) (Wright
et al., 1993). This repeat also contains an ORF, referred to as DUX4c,
which encodes a protein identical to DUX4 from the N-terminus
through the homeodomains, but the last 82 amino acids have been
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suggests that DUX4c may be expressed in FSHD samples (Ansseau
et al., 2006).Fig. 1. iC2C12-DUX4c. (A) 4q35 and FSHD candidate genes. The subtelomeric region of chromo
canbedeterminedbySouthernblot using EcoRI digestion. The locations of candidate FSHDgen
within a truncated, inverted D4Z4 repeat. DUX4 and DUX4c open reading frames are shown in
brown. (B) Western blot analyses of time–response at 1000 ng/ml doxycycline (left) and dos
localization ofDUX4c (red) during a time course of induction (1000 ng/ml doxycycline) shownb
DUX4c-expressingmyoblasts (dox 1000 ng/ml) after 24 h of induction. (E) Cell viability (ATP as
100 and 500 ng/ml doxycycline. In the ATP assay the experimental groups were compared to
average±STDEV (ATP assay, n=8; cell counts, n=3).In this study, using a conditional, regulated gene expression
system, we have analyzed the effect of DUX4c expression on C2C12
myoblast differentiation. We demonstrate that DUX4c down-some 4 bears D4Z4 repeats. Each repeat encodes DUX4 (red). The size of the D4Z4 repeats
es aremarkedwithblue boxes.DUX4c, is located42kbproximal to theD4Z4 repeats (pink)
orange and the 2 homeoboxes in black. The domain of sequence divergence is shown in
e–response of DUX4c in iC2C12-DUX4c after 24 h of treatment (right). (C) Intranuclear
y immunofluorescence.Nucleiwere counter-stainedwithDAPI (blue). (D)Morphologyof
say) and cell numbers of iC2C12-DUX4c and iC2C12myoblasts after 24 h of inductionwith
the control (0 ng/ml doxycycline) and presented as fold difference. Results are shown as
Fig. 2.DUX4c interfereswithmyogenic transcription factors. Real Time RT-PCR analyses ofMyoD andMyf5mRNAexpression over a time course (A; dox 500 ng/ml) and dose–response
after 24 h of DUX4c induction (B). Expression level for each gene was normalized to the expression level of GAPDH and then compared to the control group (0 ng/ml doxycycline).
Results represent fold difference (y-axes) compared to control which is taken to be 1. Error bars are STDEV (n=3, pb0.05). MyoD and Myf5 expression was observed to decrease
according to the level and time of DUX4c induction. (C) RT-PCR results were confirmed by analysis of MyoD expression by western blotting of extracts from dose–response (24 h of
induction) and time course inductions of DUX4c. (D) Immunofluorescence detection of MyoD (red) over a 24 h time course of DUX4c induction (dox 500 ng/ml). Nuclei were counter-
stainedwithDAPI (blue). (E) Real Time RT-PCR forMyoDandMyf5 in iC2C12 cells (parent cell line) treatedwith 1000 ng/ml doxycycline during the period of 24 h. Results are presented
as fold difference compared to the control (0 ng/ml).
89D. Bosnakovski et al. / Experimental Neurology 214 (2008) 87–96regulates expression of myogenic transcriptional factors MyoD, Myf5
and myogenin. This interaction with myogenic regulators correlates
with diminished myoblast fusion and terminal myotube differentia-tion even at low levels of DUX4c expression. Overexpression of MyoD
orMyf5 in DUX4c-expressing cells rescued their ability to differentiate
suggesting that they are the key downstream genes that mediate this
90 D. Bosnakovski et al. / Experimental Neurology 214 (2008) 87–96effect. Our results predict that DUX4c expression would have a
deleterious effect on muscle regeneration, and could therefore play a
role in FSHD pathogenesis.
Results and discussion
DUX4c-inducible myoblasts
Wemodifiedmouse C2C12 myoblasts to enable conditional DUX4c
expression by inserting the cDNA for DUX4c into the inducible locus of
iC2C12, a C2C12 subclone that expresses rtTA and carries a
tetracycline-inducible locus that can be targeted by cre–lox recombi-
nation (manuscript submitted). The parent iC2C12 cell line has a
cassette exchange recombination locus which allows efficient gene
targeting. The integration site of this locus was selected for absence of
leakiness and minimal silencing. The principal advantage of this
system is that genes can reliably and predictably be expressed in a
conditional dose-dependent manner. Because DUX4c, like DUX4, is
likely to be expressed at very low levels (Kowaljow et al., 2007; Dixit
et al., 2007), it is critical to be able to titrate expression down to levels
barely detectable bywestern blot. However, to facilitate the evaluation
of downstream target genes and other potential physiological effects,
rapid high-level expression is also necessary. We evaluated expression
in the DUX4c-inducible myoblasts, which we named iC2C12-DUX4c,
using a monoclonal antibody that was raised against DUX4 and cross
reacts to DUX4c (Dixit et al., 2007). When exposed to doxycycline,
iC2C12-DUX4c cells overexpress human DUX4c in a dose-dependent
manner with rapid kinetics (Fig. 1B). At high levels of expression
(1000 ng/ml doxycycline) DUX4c was expressed in virtually all cells
within 4 h, and was exclusively localized to the nucleus, as shown by
immunofluorescence (Fig. 1C). Homeodomain proteins are nuclear
transcription factors, and in many cases localization depends on a
nuclear localization signal (NLS) residing within the homeodomain
itself (Hessabi et al., 1999). In the case of DUX4, fluorescence
photobleaching of a constitutively expressed GFP fusion protein
showed that the DUX4 homeodomain contains an NLS, and that the
protein resides primarily in the nucleus (Ostlund et al., 2005).
At 24h post-induction, the morphology of DUX4c-expressing
myoblasts appeared normal (Fig. 1D) and cell viability as measured
by an ATP assay was unaffected (Fig. 1E). To control for doxycycline-
specific effects that might be unrelated to DUX4c expression, we
tested the iC2C12 parent (non-DUX4c-expressing) cell line, and no
doxycycline-induced changes were observed (Fig. 1E). Furthermore,
after 6 days of continual exposure to doxycycline, we did not detect
any changes inmorphology or viability of the parent iC2C12 cells (data
not shown). Unlike DUX4c and DUX1, DUX4 is toxic in myoblasts and
its expression correlates with apoptosis, indicated by activation of
caspases 3 and 7 followed by increased lactate dehydrogenase (LDH)
activity and positive staining for Annexin V (Kowaljow et al., 2007 and
D.B., M.K., unpublished results). FHSD-affected myoblasts have been
reported to exhibit morphological abnormalities, including a swollen
and irregular cytoplasm containing numerous vacuoles (Winokur
et al., 2003a). Given the lack of morphological changes in iC2C12-
DUX4c cells even at high levels of DUX4c expression, the abnormalFig. 3. DUX4c diminishes myogenic differentiation. (A) Morphology of iC2C12-DUX4c cells a
with 30 or 100 ng/ml doxycycline. Note abundant myotube formation in the control group
Immunofluorescence detection of myosin heavy chain (MyHC, red) at day 4 of differentiation
which confirms that myogenic differentiation was blocked by DUX4c induction. (C) The lev
within myotubes as percent of total number of nuclei). Error bars are STDEV with n=5. (D) R
MCK and desmin revealing significant inhibition of differentiation. Relative expression level
presented as fold difference (y-axes). Values are given as average±STDEV. (E) Morphology of
were treated with 100 ng/ml doxycycline during the entire course of differentiation (4 days)
(red) and nuclear staining with DAPI (blue) confirmed that cells underwent terminal differe
showing similar differentiation ability in the presence and absence of 100 ng/ml doxycycline
of differentiation confirming that doxycycline alone (≤300 ng/ml) does not have any effect
control (0 ng/ml doxycycline).morphology of FSHD-affectedmyoblasts is therefore unlikely to be due
to DUX4c, and is probably mediated by other candidate genes,
including DUX4.
DUX4c interferes with myogenic transcriptional factors
We next evaluated whether DUX4c expression had any effect on
the ability of C2C12 myoblasts to differentiate into multinucleated
myotubes. This process involves the sequential activation of myogenic
regulatory factors by the homeodomain-containing transcription
factors Pax3 and Pax7, therefore we first evaluated expression of
MyoD and Myf5, two well known targets of Pax3 and Pax7 (Tajbakhsh
et al., 1997; Bajard et al., 2006). In proliferating myoblasts, the levels of
expression of MyoD and Myf5 were inhibited by DUX4c, starting as
early as 4 h post-induction with 500 ng/ml doxycycline (Fig. 2A). This
inhibition increased in a time- and dose-dependent manner (Figs. 2A
and 2B). Significant down-regulation of Myf5 and MyoD was detected
in the cells treated with as little as 8 ng/ml doxycycline for 24 h (Fig.
2B). By western blot and immunofluorescence, down-regulation of
MyoD protein was evident within 8 h of high-level (500 ng/ml
doxycycline) DUX4c induction (Figs. 2C and 2D). Even lower doses of
DUX4c (16–32 ng/ml of doxycycline) were sufficient for almost
complete suppression of MyoD within 24 h (Figs. 2BB and 2C). On
the other hand, doxycycline by itself did not have any significant
influence on MyoD or Myf5 in the non-DUX4c-expressing parent cell
line, iC2C12 (Fig. 2E).
Expression profiling in FSHD patients has demonstrated that genes
with altered expression include many involved in myogenic differ-
entiation and represent targets of the muscle-specific transcriptional
factor MyoD (Winokur et al., 2003b). Different subsets of MyoD target
genes were affected in different groups of FSHD patients, categorized
according to the number of the remaining D4Z4 repeats (Celegato
et al., 2006). For this reason it has been proposed that interference
with an early sub-program of MyoD-mediated muscle cell differentia-
tion is one mechanism underlying FSHD (Winokur et al., 2003b). Our
results show a strong correlation between DUX4c and MyoD, with
DUX4c expression inducing rapid down-regulation of MyoD (Fig. 2).
MyoD andMyf5 are skeletalmuscle-specific geneswhich belong to the
basic-helix-loop-helix family of proteins and are necessary and
sufficient for myogenesis (Weintraub et al., 1991). Mice lacking both
MyoD and Myf5 have a complete absence of skeletal muscle,
demonstrating a critical role for these factors in myogenesis (Rudnicki
et al., 1993). Taken together, the importance of MyoD in myogenesis
and its misregulation in FSHD makes this property of DUX4c
particularly interesting and possibly a factor in the pathology of
FSHD. The reduced expression of MyoD may be explained by a direct
interaction between DUX4c and the MyoD gene, although we have no
evidence for this at the present time, or it may be mediated by an
intermediary factor.
DUX4c abolishes myogenic differentiation
The ability of DUX4c to inhibit MyoD and Myf5 expression
suggested that DUX4c-expressing myoblasts may show a phenotypefter 4 days of differentiation in medium supplemented with 2% HS. DUX4c was induced
and only dense monolayer culture with sporadic small myotubes in treated groups. (B)
. Note staining in the control and absence of staining in the doxycycline-treated group,
el of differentiation was quantified by evaluation of the myotube fusion index (nuclei
eal Time RT-PCR analyses for expression of myogenic differentiation markers myogenin,
for each gene was compared to the control group (0 ng/ml doxycycline) and results are
control parental iC2C12 after 4 days of differentiation in medium containing 2% HS. Cells
and no morphological abnormalities were observed. (F) Immunofluorescence for MyHC
ntiation in the presence of doxycycline. (G) Myotube fusion index for the control cells
(n=3). (H) Real Time RT-PCR for myogenin, desmin and MCK in iC2C12 cells after 4 days
on expression of these genes. Results are presented as fold difference compared to the
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expressing myoblasts to differentiate into myotubes by growing them
to confluence and withdrawing growth factors (switching to medium
supplemented only with 2% horse serum). In the absence ofdoxycycline, iC2C12-DUX4c cells differentiated en masse into multi-
nucleatedmyotubes, however in the presence of doxycycline, added at
the time differentiation was induced, cells failed to fuse and did not
form myotubes (Fig. 3A). The inhibitory effect was morphologically
92 D. Bosnakovski et al. / Experimental Neurology 214 (2008) 87–96evident over the entire process of differentiation (4–6 days). Remark-
ably, the effect was significant even when the cells expressed low
levels of DUX4c (30 ng/ml doxycycline) in which only sporadically
fused small myotubes were observed (Fig. 3A). The effect on
differentiation was dose-dependent and more severe with higher
DUX4c expression.
To determine whether differentiation per se was blocked, or cells
were merely failing to fuse, we evaluated molecular markers of
differentiation. The differentiation defect was supported by immuno-
fluorescence for myosin heavy chain (MyHC), which was either
sporadic (30 ng/ml dox) or completely absent (100 ng/ml, Fig. 3B). ItFig. 4. Overexpression of MyoD or Myf5 rescues the DUX4c block tomyogenic differentiation
Myf5-ires-GFP (Myf5) or MSCV-hMyoD-ires-GFP (human (h) MyoD). The green population
transduced cells were used as a control to set up the gate (left). (B)Morphology of iC2C12-DUX
4 days of differentiation. Cells were treated with doxycycline during the 4 days in myogenic
hMyoD-transduced cells even at 50 ng/ml doxycycline, where they are completely abolished
and mouse MyoD after 4 days of differentiation (sample from B; n=3). Expression levels of ea
as fold difference compared to control (0 ng/ml, y-axes). Error bars represent STDEV with n
blue) at day 4 of differentiation. DUX4c was induced with 12.5 and 25 ng/ml doxycycline duri
shown in 4D.was also supported by a greatly reduced myotube fusion index
(percent of nuclei within multinuclear myotubes, Fig. 3C). Untreated
iC2C12-DUX4c, the control group, differentiated at the expected level
with 50–60% of nuclei present in fusion derivatives (Fig. 3C and Fig.
4G). In addition, Real Time RT-PCR revealed significantly reduced
expression of myogenin, desmin and muscle creatine kinase (MCK)
even in samples which were treated with only 10 ng/ml doxycycline
(Fig. 3D). At this low concentration of doxycycline, DUX4c is barely
detectable by western blot. This is significant, as the relevant FSHD
candidate gene may be expressed at very low levels and difficult to
detect in patient biopsies. To control for potential effects of. (A) FACS analyses of iC2C12-DUX4c cells transduced with MSCV-ires-GFP (GFP), MSCV-
shifted on the x-axis represents the transduced fraction at day 2 post-infection. Non-
4c cells transducedwith retroviruses carryingMyf5, hMyoD or empty vector (GFP) after
differentiation medium (DMEM/2% HS). Myotube formation was evident in Myf5- and
in the empty vector control. (C) Real Time RT-PCR for DUX4c, myogenin, desmin, MCK
ch gene were normalized to the expression level of GAPDH, and results were presented
=3 and pb0.05. (D) Immunofluorescence for MyHC (red), GFP (green) and nuclei (DAPI,
ng the period of differentiation (4 days). (E) Myotube fusion index calculated for the cells
Fig. 4 (continued).
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of experiments with the parental non-DUX4c-expressing iC2C12 cell
line. During 4 days of differentiation, the presence of 100 ng/mldoxycycline had no effect (Fig. 3E). Positive immunofluorescence
staining for MyHC confirmed that doxycycline-treated iC2C12 (par-
ental control) cells differentiated appropriately into multinuclear
94 D. Bosnakovski et al. / Experimental Neurology 214 (2008) 87–96myotubes (Fig. 3F). We did not detect any significant alteration in the
myoblast fusion index in response to doxycycline alone (Fig. 3G) nor in
the expression of myogenic differentiation markers by Real Time RT-
PCR analyses (Fig. 3H). We therefore conclude that these effects are
specific to DUX4c.
Overexpression of MyoD or Myf5 rescues the DUX4c myogenic
differentiation blockade
Because reduced levels of MyoD and Myf5 in myoblasts under
both proliferation and differentiation conditions correlated with the
inability of DUX4c-expressing cells to differentiate, and because
these two genes are critical regulators of myogenic differentiation,
we reasoned that the principal reason for the lack of differentiation
was the lack of expression of the necessary bHLH factor. To test this
hypothesis, we used an independent vector to express MyoD or
Myf5 in DUX4c-expressing myoblasts, and repeated the differentia-
tion experiments, above. An MSCV retroviral vector expressing
cDNAs of human MyoD, mouse Myf5, or empty control, followed by
ires-GFP for tracking positive cells, was introduced into subconfluent
iC2C12-DUX4c cells. Human MyoD was selected for these experi-
ments in order to allow independent tracking of the effect of DUX4c
on expression of the mouse MyoD gene at the RNA and protein
level. Two days post-infection, the transduction rate was deter-
mined by FACS analysis in one arm. We used transductions in which
the rate approached 50% in order to be able to measure differ-
entiation potential of transduced (green fluorescent) and non-
transduced cells side by side. Myoblasts were then switched to
differentiation medium (DMEM/2% HS) and DUX4c was induced
over a dose-series. At day 4 of differentiation in the controls (0 ng/
ml doxycycline) of all of the experimental groups GFP, Myf5 or
hMyoD, complete terminal myotube differentiation was observed
(Fig. 4B). As expected, DUX4c-expression, even under 12.5 ng/ml
doxycycline, prevented myotube formation in the empty vector-
transduced cells. On the other hand, obvious differentiation,
characterized by fused, elongated myotubes, was observed in
hMyoD- or Myf5-transduced cells (Fig. 4B).
Real Time RT-PCR analyses for DUX4c confirmed its dose-
dependent induction in all samples (Fig. 4C). RT-PCR analyses for
myogenin, desmin, and MCK also confirmed that differentiation was
blocked in DUX4c-induced cells coexpressing GFP, but allowed in
Myf5 andMyoD coexpressing cells (Fig. 4E). By using humanMyoD for
these studies, we were able to independently analyze expression from
the mouse MyoD gene. Irrespective of exogenous Myf5 or MyoD,
DUX4c was still able to repress the mouse MyoD gene, indicating that
the exogenous bHLH factors were not inhibiting DUX4c activity
directly, but are acting in classical epistatic fashion, downstream of
DUX4c.
Differentiation was confirmed by immunofluorescence for
MyHC (Fig. 4D). To demonstrate that rescue was specific to cells
expressing the rescue constructs, we performed double staining for
GFP and MyHC. Virtually all of MyHC positive cells were GFP-
positive while undifferentiated cells were GFP-negative (Fig. 4D),
indicating that rescue was specific to that portion of cells that had
been transduced with the bHLH factor. To quantify the level of
differentiation we analyzed the myotube fusion index. Myf5 or
MyoD overexpressing cells demonstrated significant levels of
myotube fusion (Fig. 4E).
It was notable that although hMyoD and Myf5 were clearly able to
rescue differentiation, the extent of rescue was reduced both in terms
of the myotube fusion index and in the size of individual myotubes as
doxycycline was titred to higher levels. This was in spite of MyoD
target genes, myogenin, desmin, and MCK being fully rescued to
wild-type (no dox) levels. This suggests that additional unknown
factors in addition to MyoD/Myf5, and their direct target genes, are
necessary for regulating the extent of differentiation and the size ofmyotubes, and implies that DUX4c may interfere with these factors
as well.
Conclusion
In summary, we have shown that DUX4c does not have toxic effects
on myoblasts while proliferating, but that it interferes with the
expression of myogenic regulators and inhibits differentiation of
myoblasts, even at very low levels of expression. Diminished differ-
entiation is in large part due to down-regulation of the crucialmyogenic
transcription factors MyoD and Myf5. As myogenesis is necessary for
homeostatic maintenance of muscle, if DUX4c were expressed as
satellite cells undergo cycles of regeneration, it would be predicted to
reduce the efficiency of regeneration by interferingwith differentiation.
The fact that FSHD manifests in individuals with fully developed
musclesmeans that DUX4cmust not be expressed during development
at levels that would completely block all differentiation, however by
reducing the efficiency of differentiation, DUX4c would be predicted to
place an extra burden on the stem cell compartment in FSHD-affected
individuals leading to early depletion of regenerative potential. Scant
data exists on the expression of DUX4c (or DUX4) in adults or embryos
(Kowaljow et al., 2007; Dixit et al., 2007; Ansseau et al., 2006).
DUX4c is not likely to be solely responsible for FSHD— recent work
has shown that FRG1, when overexpressed specifically in differen-
tiated muscle of transgenic mice, causes a myopathic phenotype
(Gabellini et al., 2006). The interference with regeneration described
above could enhance the severity of a primary defect caused by FRG1
or another FSHD candidate gene. There has been recent debate over
the relevance of FRG1, given the high levels of expression required to
elicit its phenotype in mice. By inhibiting regeneration, DUX4c could
potentially reveal a latent phenotype of low level expression of FRG1.
Although the search for the proximal effector of FSHD has focused on
identifying the key gene, it is also possible that the complicated FSHD
phenotype represents the combinatorial action of more than one
4q35.2 gene. It will therefore be interesting to look for synergy in
transgenic models employing combinatorial low level expression of
DUX4c and other FSHD candidate genes.
Materials and methods
Cell culture
C2C12 cells were cultured in proliferation medium consisting of
high glucose Dulbecco's Modified Eagle Media (DMEM) supplemented
with L-glutamine and sodium pyruvate (Gibco), penicillin and
streptomycin (P/S, Gibco) and 20% fetal bovine serum (FBS, Atlanta
Biologicals) at 37 °C in 5% O2/5% CO2. For myotube formation, C2C12
cells were cultured on gelatin-coated dishes in proliferation medium
until confluence, and then washed with serum-free DMEM and
differentiated with DMEM supplemented with 2% horse serum (HS,
Sigma) and 10 μg/ml insulin (Sigma) for 4–6 days. Cell images were
captured on an Olympus IX70 microscope (Olympus Optical, Tokyo,
Japan) with a Nikon DXM1200 digital camera (Nikon, Tokyo, Japan)
and Nikon ACT-1 software.
Generation of DUX4c inducible myoblast cell line (iC2C12-DUX4c)
DUX4c was subcloned from pCLneo-DUX4c as XbaI/EcoRI fragment
into pBS in order to acquireXhoI andNotI cloning sites,whichwere then
used for sub-cloning into p2lox to generate p2lox-DUX4c. iC2C12 cells
were transfectedwith p2Lox-DUX4c, and selected in 800 ug/ml of G418.
Cell viability and proliferation
For ATP assay, iC2C12-DUX4c and iC2C12 were plated in a 96 well
plate (2400 cells/well). DUX4c was induced the following day with
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post-induction by measurement of ATP (Molecular Probes, Eugene,
OR) following the manufacturer's protocol. To assay the ATP, medium
was removed, cells were lysed with 50 ul of ATPlite and luminescence
was read on a POLARstar Optima Microplate Reader (BMG LABTECH,
Offenburg, Germany). The absolute level of luminescence was
normalized to the control (0 ng/ml doxycycline) and the results
were represented as fold difference. For analyses of cell proliferation
10,000 iC2C12-DUX4c cells were plated in each well of 12-well plates.
The following day DUX4c was induced by 0, 100 and 500 ng/ml
doxycycline for 24 h. The cell numberwas determined by counting live
cells with a hemocytometer (n=3).
Western blotting
Cells were lysed for 30 min at 4 °C with RIPA buffer (Santa Cruz)
supplemented with a protease inhibitor cocktail (Roche). Proteins
were separated by electrophoresis on 10% PAGE gels (Bio Rad). The
gels were then transferred to PVDF membranes (Bio Rad), and
membranes were blocked in 5% skim milk in TBS-T (Tris-buffered
saline with 0.01% Tween-20) for 1 h at room temperature. Primary
antibodies: mouse monoclonal anti-DUX4 (1:2000, Dixit et al., 2007),
mouse anti-MyoD (1: 250, BD Biosciences) were added in the same
milk mixture and incubated overnight at 4 °C. Anti mouse horseradish
peroxidase-conjugated secondary antibody (1:3000, Santa Cruz) was
incubated for 1 h at room temperature. Proteins were detected by
applying ECL Plus (GE Healthcare) to the membrane and exposure to
X-ray film. For normalization, membrane was striped by 100 mM 2-
mercaptoethanol and 2% SDS in 0.5 M Tris buffer for 30 min and
reprobedwithmonoclonal mouse anti-actin (1:2000, Sigma) antibody
for 30 min at room temperature.
Immunofluorescence
Cells were cultured on gelatin-coated coverslips, fixed with 4%
paraformaldehyde for 20 min, permeabilized by 0.3%Triton X-100 for
30 min and blocked by 10% goat serum for 1 h at room temperature.
Primary antibodies (anti-DUX4, anti-MyoD and mouse anti-myosin
heavy chain (1:20, Hybridoma bank)) were incubated in PBS/2% goat
serum at 4 °C overnight, followed by anti-mouse Cy3-conjugated
secondary antibodies (1:400, Sigma) at room temperature for 45 min.
For detection of GFP, polyclonal chicken anti-GFP antibody (1:500,
AbCam) as primary and Alexa Fluor 488 (1:500, Invitrogen) as
secondary antibody were used. Cells were counter-stained using
4′,6-diamidino-2-phenylindole (DAPI, Invitrogen) to visualize nuclei
and mounted in “Immu-Mount” (Thermo Scientific, Pittsburg, USA).
The images were visualized with an Olympus BX50 microscope, an
Olympus U-CMAD digital camera, and MetaVue 5.0 software.
Quantitative Real Time RT-PCR (qRT-PCR)
Total RNA was extracted with Trizol (Invitrogen) and cDNA was
generated using 1 μg DNase-treated RNA with oligo-dT primers and
TermoScript polymerase (Invitrogen). PCR was performed by using
p re -made pr imer s /p robe s (GAPDH Mm99999915_g1,
MyoD1Mm00440387_m1, Myf5Mm00435125_m1, myogenin
Mm0 0 4 4 619 4 _m1, d e sm i n Mm0 080 24 5 5 _m1, MCK
Mm00432556_m1, DUX4c Hs02386627_gh all from Applied Biosys-
tems) with TaqMan Real Time PCR premixture and run on an Applied
Biosystems 7500 real time PCR System. For detecting of human
MyoD1, we designed intron-spanning primers (forward: cactccggtcc-
caaatgtag and reverse: ttccctgtagcaccacacac) and Power SYBR Green
PCR Master Mix (Applied Biosystems) was used. PCR conditions were
standard for the Applied Biosystems pre-made probesets: 95 °C for
15 s; 60 °C for 60 s 7500 real time PCR System. Glyceraldehyde
phosphate dehydrogenase (GAPDH)was used as the internal standard.Gene expression was normalized and analyzed using delta Ct method
by 7500 System Software (Applied Biosystems). Results were
presented as fold difference compared to the control (ddCt) or fold
difference compared to the GAPDH (1/power(2/dCt)). All reactions
were performed at least in triplicate and the error bar is STDEV.
Cloning of Myf5 and hMyoD retroviral vectors and virus production
Mouse Myf5 cDNA from pCR4-TOPO-Myf5 (ID 40130421, Open
Biosystems) was subcloned as an EcoRI fragment into pMSCV-ires-GFP
to generate pMSCV-Myf5-ires-GFP. Human MyoD cDNA from pOTB7-
hMyoD1 (ID 5022419 Open Biosystems) was subcloned as EcoRI/XhoI
fragment into pMSCV-ires-GFP to generate pMSCV-hMyoD-ires-GFP.
Retroviral supernatants were produced in 293T cells cultured in
DMEM/10% FBS. Viral constructs were co-transfected with pCL-Eco
packaging constructs (Naviaux et al., 1996). Mediumwas changed after
24 h and the viral supernatant was collected at 48 h post-transfection.
Filtered supernatant (0.45 μm) was applied to the subconfluent cells
with polybrene (4 μg/ml). Spin-infectionwas performed at 2500 r.p.m.
at 33 °C for 90 min. Cells were incubated for additional 12 h at 37 °C
after which time the supernatant was replaced with fresh medium.
Two days post-infection, proliferation medium was switched to
myoblast differentiation medium (DMEM with 2% HS) and treatment
with doxycycline was started. To evaluate the infection efficiency at
day 2 post-transduction, cells were trypsinized and analyzed for GFP
expression by flow cytometry (BD FACS Aria). The expression of the
inserted gene was also confirmed by RT-PCR.
Statistical analyses
All experiments were done at least 3 times. Data shown for Real
Time RT-PCR and myotubes fusion index are the mean±STDEV.
Difference between means was compared by the two-tailed Student
test (GraphPad Prism 5) and was considered significantly different at
Pb0.05.
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